Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.

F, Cappuzzo; E, Magrini; GL, Ceresoli; S, Bartolini; E, Rossi; V, Ludovini; V, Gregorc; C, Ligorio; A, Cancellieri; S, Damiani; A, Spreafico; CT, Paties; L, Lombardo; C, Calandri; G, Bellezza; M, Tonato; L, Crinò

doi:10.1093/jnci/djh217

Public

Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.

Shared by NobleBlocks on Aug 1, 2004 • 12:00 AM UTC

Authors:

Cappuzzo F

Magrini E

Ceresoli GL

Abstract

<h4>Background</h4>Gefitinib, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has activity against approximately 10% of unselected non-small-cell lung cancer (NSCLC) patients. Phosphatidylinositol 3'-kinase (PI3K)/Akt and Ras/Raf/mitogen-activated protein kinase (MAPK),...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!